A Phase 3 interventional study of Dulaglutide 1.5 MG/ML and Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution in Obese Diabetics and Obese Non Diabetic, sponsored by Zagazig University. Completed at 1 site in Saudi Arabia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Zagazig University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 27th largest by enrollment, is one of 4 that started in 2025, is one of 22 in phase 3, and was the 54th registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 159 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Zagazig University is the lead sponsor of 461 studies on the registry; 78 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Zagazig University has 3 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
titel : Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial
Abstract :
Background: This study that highlights the different effects of most used three GLP-RA Dulaglutide, Semaglutide, Tirazepetide among diabetic and non -diabetic participant as the well-known fact that they don't have only weight recuing effect but also many different effects on metabolic process including insulin sensitivity, lipid profile and NASH.
Materials and Methods:
This is a randomized controlled study involving a total of 159 participants, divided into 75 non-diabetic and 84 diabetic obese individuals. Participants were assigned to three drug groups, each receiving a once-weekly dose of Dulaglutide, Semaglutide, or Tirzepatide for a period of 24 weeks. Each drug group consisted of 53 individuals, subdivided into 25 non-diabetic and 28 diabetic participants.
Measurements were taken at three time points: pretreatment, 3 months post-treatment, and 6 months post-treatment. Each participant underwent a complete physical exam, and data was collected on weight, BMI, age, and sex and Laboratory tests. , also repeated measurements were taken at 3 and 6 months post-treatment. on metabolic processes, weight reduction, and insulin sensitivity, particularly in diabetic individuals, as well as effects on lipid profiles and liver enzymes, weight reduction, BMI, HbA1c, TYG-index, triglycerides, and HDL-C levels. total cholesterol (Tc) and liver enzymes.
Data were collected, and statistical analyses were conducted afterward.
Methods
Study and population:
This was a randomized controlled clinical trial study conducted at Al-Zafer hospital Najran KSA October 2025. The study received approval from the Institutional Ethics Committee (king Khaled hospital) Najran health cluster KSA on 27 October 2024. IRB registration number with KACST, KSA: H-11-N-136.
Definition of overweight and obesity in adults using Body mass index (BMI): BMI ≥ 25 kg/m² (overweight) and BMI ≥ 30 kg/m² (obesity).
Formula: Body mass index, kg/m2 = weight, kg / (height, m)2 [24] Facts \& Figures Simental-Mendia et al. (2008) developed the TyG (Triglyceride-Glucose Index), a mathematical equation that indirectly evaluates IR based on laboratory data: fasting plasma triglycerides and glucose levels [25].
Grouping This study was conducted on a total of 159 participants who attend the outpatient internal medicine clinic.
Group 1: included 53 subjects: 25 non-diabetics and 28 diabetics receiving dulaglutide.
Group 2: included 53 subjects: 25 non-diabetics and 28 diabetics receiving semaglutide.
Group 3: included 53 subjects: 25 non-diabetics and 28 diabetics receiving tirzepatide.
The study will be done from October 2025 to March 2026.
Subject included lithe study:
Inclusion criteria: A minimum of 24 weeks of follow-up was required for adults (18-65 years old) who were either overweight or obese, diabetic, or non-diabetic and had received GLP-1RAs.
Exclusion criteria: In a crossover design, GLP-1RA is compared to other drug classes without a placebo arm or using withdrawn medications. Patients who will refuse to be enrolled in the study or refuse to sign the consent will be also excluded.
Method of selection of sample: the sample will be selected by randomized method.
Sample size: Sample size was calculated using G*Power for a mixed-design ANOVA with two between-subject factors (3×2 design) and one within-subject factor (3 repeated measurements). The total sample size was estimated to be 114 participants, with 19 participants in each group, assuming a medium effect size (f = 0.25) for α = 0.05, power = 99%, and a correlation of 0.5 among repeated measures.
All participants underwent:
Full history taking: with special consideration to age, sex, and location of residence and gastrointestinal symptoms, General examination: The body mass index was determined by dividing the weight (in kilograms) by the square of the height (in meters) with particular attention to weight and height. The Centers for Disease Control and Prevention (CDC) classified individuals with a body mass index (BMI) below 18.5 as underweight. Normal is defined as a body mass index (BMI) between 18.5 and 24.9, 25 to 29.9 is considered overweight, and 30 and above is considered obese), Laboratory investigation: includes fasting blood glucose (FBS), lipid profile TC (Total Cholesterol, Triglycerides (TG), LDL (Low Density Cholesterol), HDL (High Density Cholesterol), liver enzymes (ALT, (Alanine Aminotransferase) AST (Aspartate Aminotransferase), HBA1C using device VITROS product chemistry with LDHI slides kits Ortho-clinical Diagnostics USA and Tyg index (insulin resistance).
Data analysis:
Information was entered and evaluated using IBM-SPSS software for Windows, version 27, 2020, developed by IBM SPSS Inc. in Chicago, Illinois, USA. Numerical data are presented as the median (Q1-Q3), while categorical data are expressed as N (%). Comparisons among groups for numerical variables were conducted using the Kruskal-Wallis H-test, and comparisons for categorical variables were made using the Chi-square test. The correlation between two categorical variables was assessed using a 3-way ANOVA test. A binary outcome variable was predicted based on one or more predictors through binary logistic regression analysis. Statistical significance was defined as a p-value less than 0.05, accompanied by a 95% confidence interval.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
GLP1-RA
Drug: Dulaglutide 1.5 MG/ML · Drug: Dulaglutide 0.75mg subcutaneous injection
GLP1-RA
Drug: Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution · Drug: Semaglutide 1.0 mg
GLP1-RA
Drug: Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician · Drug: Tirzepatide (Flexible titration)
GLP1-RA
Drug: Dulaglutide 1.5 MG/ML
GLP1-RA
Drug: Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution · Drug: Semaglutide 1.0 mg
GLP1-RA
Drug: Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician · Drug: Tirzepatide (Flexible titration)
Drug page: Dulaglutide
once weekly dulaglutide injection
Drug page: Semaglutide
once weekly
once weekly tirzeptide 7.5 and 15 mg
once weekly
once weekly
once weekly
change in body weight at 3 and 6 months
Change from baseline in body weight (kg) at 3 and 6 months among diabetic and non-diabetic participants receiving weekly GLP-1 receptor agonists.
Time frame: 6-MONTH STUDY PERIOD
Change in Body Mass Index (BMI)
Change in BMI from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in diabetic and non-diabetic participants. Unit of Measure: kg/m²
Time frame: 3 months, and 6 months
Change in Glycated Hemoglobin (HbA1c)
Change in HbA1c from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in diabetic and non-diabetic participants. Unit of Measure: %
Time frame: Baseline, 3 months, and 6 months
Change in Low-Density Lipoprotein Cholesterol (LDL-C)
Change in LDL-C from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in diabetic and non-diabetic participants. Unit of Measure: mg/dL
Time frame: Baseline, 3 months, and 6 months
Change in Triglycerides
Change in serum triglyceride concentration from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in diabetic and non-diabetic participants. Unit of Measure: mg/dL
Time frame: Baseline, 3 months, and 6 months
Change in Alanine Aminotransferase (ALT)
Change in serum ALT concentration from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in diabetic and non-diabetic participants. Unit of Measure: U/L
Time frame: Baseline, 3 months, and 6 months
Change in Aspartate Aminotransferase (AST)
Change in serum AST concentration from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in diabetic and non-diabetic participants. Unit of Measure: U/L
Time frame: Baseline, 3 months, and 6 months
Change in High-Density Lipoprotein Cholesterol (HDL-C)
Change in HDL-C from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in diabetic and non-diabetic participants. Unit of Measure: mg/dL
Time frame: Baseline, 3 months, and 6 months
Change in Total Cholesterol (TC)
Change in TC from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in diabetic and non-diabetic participants. Unit of Measure: mg/dL
Time frame: Baseline, 3 months, and 6 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data, including demographic characteristics, baseline clinical characteristics, anthropometric measurements, laboratory results, treatment assignment, adherence data, and outcome measures collected during the study.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 2 years
Access criteria: Limited to qualified researchers conducting legitimate scientific research
Data sharing details ↗ · register.clinicaltrials.gov
Ran from Oct 2025 to primary completion in Mar 2026, 4 months.
Of 87 non-industry phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 4 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dulaglutide · Semaglutide · Tirzepatide